Core Viewpoint - Leo International Precision Health AG has approved a cash capital increase of approximately 5% by issuing 26,000 new no-par bearer shares, excluding subscription rights for existing shareholders [2][4]. Group 1: Capital Increase Details - The share capital will increase from EUR 550,000.00 to EUR 576,000.00 upon completion of the capital increase [2]. - The new shares were subscribed exclusively by Hsiao-Hsuan "Leo" Wang at a price of EUR 24.00 per share, which is about 41% above the closing price on 23 March 2026 [3]. - The gross proceeds from the capital increase are expected to amount to EUR 624,000.00 [4]. Group 2: Use of Proceeds - The company intends to use the net proceeds primarily to strengthen its equity base and support ongoing business operations [4]. Group 3: Trading Information - Upon completion, the new shares will be admitted to trading on the regulated markets of Frankfurt and Düsseldorf without a prospectus [4].

Acquisition of Own Shares - Sanoma Corporation executed a share buyback on 24 March 2026, acquiring 25,000 shares at an average price of EUR 9.0643 per share, with a total cost of EUR 226,607.50 [1] - The highest and lowest prices per share during the transaction were EUR 9.1100 and EUR 9.0100, respectively [1] Current Shareholding - Following the acquisition, Sanoma holds a total of 1,028,392 of its own shares [2] Company Overview - Sanoma is described as an innovative and agile learning and media company, impacting millions across Europe by providing high-quality learning content and solutions [2] - The company employs nearly 5,000 professionals and reported net sales of approximately EUR 1.3 billion in 2025, with an adjusted operating profit margin of 14.4% [5] Strategic Focus - Sanoma aims for organic growth in K12 education and plans to accelerate this growth through value-creating mergers and acquisitions [4] - The company is committed to sustainability, focusing on maximizing its positive impact on society while minimizing its environmental footprint, and is aligned with the UN Sustainable Development Goals [4]

Core Insights - Kitron is a leading Scandinavian electronics manufacturing services company specializing in Defence/Aerospace, Medical devices, Connectivity, Electrification, and Advanced Industry sectors [1] - The company reported revenues of EUR 738 million for the year 2025 [1] Company Overview - Kitron operates in multiple countries including Norway, Sweden, Denmark, Lithuania, Germany, Poland, the Czech Republic, India, Malaysia, China, and the United States [1] - The company employs approximately 3,300 individuals [1]

Nasdaq Copenhagen Nikolaj Plads 6DK-1067 Copenhagen K Copenhagen, 24 March 2026ANNOUNCEMENT no. 8/2026 CEMAT A/SCompany reg. (CVR) no. 24 93 28 18Annual general meeting 2026 On 24 March 2026 at 1:00 pm the annual general meeting was held in Cemat A/S (the “Company”) at DLA Piper Denmark, Oslo Plads 2, 2100 Copenhagen Ø. Pursuant to the Company’s articles of association, the Board of Directors had appointed attorney-at-law Martin Lavesen as chairman of the meeting. The management’s report on the Company’s ...

Core Viewpoint - HeartSciences Inc. is set to present at the Investor Summit Group Virtual Conference on March 25, 2026, focusing on its advancements in electrocardiography through AI integration [1][3]. Group 1: Company Overview - HeartSciences is a healthcare information technology company that enhances ECG/EKG usage via AI integration [4]. - The MyoVista Insights platform is a next-generation ECG management system aimed at improving clinical efficiency and decision-making [4]. - The MyoVista wavECG device offers conventional ECG functionality while incorporating AI-enabled solutions [4]. Group 2: Conference Details - The conference will feature a corporate presentation by CEO Andrew Simpson, discussing the company's business strategy, recent milestones, and growth catalysts [3]. - HeartSciences will engage in virtual one-on-one meetings with qualified investors on March 26, 2026 [3][6]. - Registration for one-on-one meetings can be done through the HeartSciences Investor Summit [3]. Group 3: Investor Engagement - CEO Andrew Simpson emphasized the company's commitment to expanding its investor base and increasing visibility in capital markets through participation in the conference [4].

Core Viewpoint - ChemoMetec has adjusted its revenue and EBITDA guidance for the financial year 2025/26 due to several market challenges, despite a strong competitive position in cell counting automation [1][2]. Group 1: Market Challenges - The North American market for cell and gene therapy has been impacted by government lockdowns and geopolitical uncertainties, leading to prolonged decision-making processes among customers [5]. - The implementation of automation in the production of cell and gene therapies has proven to be more time-consuming than anticipated, causing delays in validations and decisions [5]. - Increased interest in the XcytoMatic platform has resulted in a slowdown in sales of NC instruments and associated consumables [5]. Group 2: Financial Adjustments - Revenue is now expected to be in the range of DKK 490-520 million, a decrease from the previously announced DKK 565-580 million [2]. - EBITDA is projected to be between DKK 260-285 million, down from the earlier guidance of DKK 320-335 million [2]. Group 3: Competitive Position - ChemoMetec continues to see a growing number of automation projects and confirms that its XcytoMatic products remain attractive and competitive in the market [1]. - The upcoming introduction of the new software platform XM Octopus is expected to further strengthen ChemoMetec's market position [1].

Core Insights - Symbotic Inc. has been recognized as one of the World's Most Innovative Companies of 2026 by Fast Company, ranking 9 in the Robotics & Engineering category, marking its second recognition on this list [1][2]. Company Overview - Symbotic is a leader in A.I.-enabled robotics technology for the supply chain, focusing on optimizing warehouse operations for major retailers, wholesalers, and healthcare companies [3][6]. - The company's technology integrates advanced robotics, artificial intelligence, and software to enhance warehouse automation, streamline product movement, optimize inventory, improve flexibility, and reduce costs [3][6]. Industry Recognition - Fast Company's Most Innovative Companies list is a prestigious recognition that evaluates companies driving progress across various industries through a competitive application process [4][5]. - The recognition highlights organizations that not only adapt to change but also drive it, showcasing bold ideas with measurable impact [5].

Core Insights - Prenetics Global Limited has announced a strategic partnership with Superpower to connect clinical-grade supplementation with comprehensive blood diagnostics, creating a unique testing loop for consumers [1][2][3] Company Overview - Prenetics is a leading consumer health sciences company, with its flagship brand IM8 co-founded by David Beckham, focusing on premium health and longevity products [1][8] - IM8 has achieved over $100 million in annualized recurring revenue within 11 months of operations and is sold in more than 31 countries [8] Partnership Details - The partnership allows IM8 to offer Superpower's annual blood testing membership at exclusive pricing, with IM8 subscribers able to access it for $49 per year, a 75% discount from the standard price of $199 [4][7] - Superpower will feature IM8's Daily Ultimate Essentials in its personalized health protocols, providing a foundational nutritional ritual for its members [3][7] Health Industry Shift - The collaboration addresses a gap in the wellness industry by providing measurable proof of supplement efficacy through blood testing, moving from reactive treatment to proactive health optimization [2][5] - The integrated offering aims to create a closed-loop system in consumer health, where testing leads to actionable insights and results [5][7] Product Offerings - IM8's Daily Ultimate Essentials is designed to replace 16 different supplements and is NSF Certified for Sport, non-GMO, vegan, and free from common allergens [9] - Superpower offers a comprehensive health membership that includes annual blood testing across 100+ biomarkers, personalized health protocols, and 24/7 concierge care [10]

TORONTO, March 24, 2026 (GLOBE NEWSWIRE) -- Middlefield Limited is pleased to announce that Income Plus Class ETF Series (TSX: MIPC) (the “Fund”) distributions for March 2026 will be payable to unitholders of the Fund as follows: Record DatePayable DateDistribution Per Trust UnitMarch 31, 2026April 15, 2026$0.031 About Middlefield Founded in 1979, Middlefield is an income focused asset manager with offices in Toronto, Canada and London, England. Our investment team has developed a disciplined investment pr ...

Group 1 - Middlefield Limited announced the distribution details for the ActivEnergy Dividend Class ETF Series (TSX: MAEC) for March 2026, with a distribution of $0.018 per trust unit payable on April 15, 2026, to unitholders [1] - The record date for the distribution is set for March 31, 2026 [1] Group 2 - Middlefield, founded in 1979, is an income-focused asset manager with offices in Toronto and London, specializing in identifying attractive investment opportunities while managing risks [2] - The company offers a diverse range of investment solutions, including Exchange-Traded Funds, Canadian Mutual Funds, Split Share Corporations, Closed-End Funds, and Flow-through LPs, focusing on sectors such as Real Estate, Healthcare, Innovation, Infrastructure, Energy, Diversified Income, and Fixed Income [2]